

icthic.com



11th INTERNATIONAL CONFERENCE ON
**THROMBOSIS
& HEMOSTASIS
ISSUES IN CANCER**

May 27-29, 2022


Centro Congressi Giovanni XXIII - Bergamo, Italy

Hybrid edition

PROGRAM

AUSPICES

The meeting is held under the auspices of:



Società Italiana di Ematologia (SIE)



Società Italiana per lo Studio dell'Emostasi e della Trombosi



CONFERENCE ORGANIZATION

Conference Chairmen

Anna Falanga, MD

Department of Medicine and Surgery,
University of Milano-Bicocca, Monza;
Department of Immunohematology
and Transfusion Medicine,
Hospital Papa Giovanni XXIII,
Bergamo, Italy

Benjamin Brenner, MD

Rambam Health Care Campus,
Technion, Israel Institute of Technology
Haifa, Israel

Alok A. Khorana, MD, FACP

Cleveland Clinic Lerner College
of Medicine, Case Western Reserve
University
Taussig Cancer Institute, Cleveland Clinic
Cleveland, Ohio, USA

Chairman Emeritus

Frederick R. Rickles, MD, FACP

The George Washington University, Katzen Cancer Center,
Medical Faculty Associates
Washington, USA

Organizing Committee

Anna Falanga
Bergamo, Italy

Benjamin Brenner
Haifa, Israel

Alok A. Khorana
Cleveland, OH, USA

Laura Russo
Bergamo, Italy

Co-organized by

Fondazione ARTET onlus (fondazioneartet.it)



Scientific Secretariat

Anna Falanga
Marina Marchetti
Laura Russo
Alfonso Vignoli

Department of Immunohematology
and Transfusion Medicine
Hospital Papa Giovanni XXIII
Bergamo, Italy
scientificsecretariat@icthic.com

Organizing Secretariat

Servizi C.E.C. Srl Via Daste Spalenga 15 - 24125 Bergamo, Italy
info@icthic.com

PROGRAM OVERVIEW

Friday May 27th

07:00	Secretariat opening
08:15	Congress opening
08:30	Plenary session 1 Emerging trends in cancer associated thrombosis 📍 Oggioni room
10:45	Coffee break
11:15	Plenary session 2 Exploring the relationship between hemostasis and cancer: new insights 📍 Oggioni room
13:30	Lunch special lecture 📍 Oggioni room
14:30	Coffee and pastries
15:00	Plenary session 3 Role of hemostatic biomarkers in CAT and cancer progression 📍 Oggioni room
17:30	Tea break
18:00	Debate Catheter-associated thrombosis in cancer patients: to prophylax or not to prophylax? 📍 Oggioni room
19:00	Plenary lecture 7th Simon Karpatkin Memorial Lecture 📍 Oggioni room
20:00	Welcome reception









Saturday May 28th

07:45	Secretariat opening
08:30	Plenary session 4 Hemostatic complications and novel anti-cancer therapies 📍 Oggioni room
10:45	Coffee break
11:15	Plenary session 5 Covid-19, thrombosis and cancer 📍 Oggioni room
13:30	Satellite symposia 📍 see pages 30-31
14:30	Coffee and pastries
15:00	Poster discussion sessions 📍 see pages 17-24
17:30	Roundtable Multidisciplinary approach in cardiovascular oncology 📍 Oggioni room
18:30	
20:30	Presidential dinner (by invitation only)

Sunday May 29th

07:45	Secretariat opening
08:30	Plenary session 6 Cardiovascular complications in cancer patients 📍 Oggioni room
10:45	Debate Duration of VTE treatment beyond 6 months: to continue or not to continue? 📍 Oggioni room
11:45	Brunch
12:45	Plenary session 7 Prevention and treatment of cancer-associated thromboembolism 📍 Oggioni room
15:40	Concluding remarks



LEGEND

	Congress opening
	Lunch Special lecture Plenary Lecture
	Plenary session 1-7
	Round table
	Debates
	Concluding remarks
	Satellite symposia
	Poster discussion sessions

CONGRESS CENTER MAP


Groundfloor

- 1 Reception – Registration area
- 2 Oggioni room – Conference room
- 3 Sala vip – Slide center
- 4 Foyer – Catering area
- 5 Hall bar – Catering area



First floor

- 6 Stucchi room – Catering area
- 6 Giardino pensile – Catering area
- 7 Bianca room – Conference room



Second floor

- 8 Alabastro room – Conference room
- 9 Novelli room – Conference room
- 10 Stampa room
- 11 Business room
- 12 Smart room

FACULTY

Pantep Angchaisuksiri - Thailand

Cihan Ay - Austria

Rupert M. Bauersachs - Germany

Benjamin Brenner - Israel

Suzanne C. Cannegieter - The Netherlands

Marc Carrier - Canada

Elisabetta Castoldi - The Netherlands

Alexander Cohen - UK

Jean M. Connors - USA

Erica De Candia - Italy

Valerio De Stefano - Italy

Aurélien Delluc - Canada

Marcello Di Nisio - Italy

Ismail Elalamy - France

Elena Faioni - Italy

Anna Falanga - Italy

Josè Javier Fuster - Spain

Grigoris T. Gerotziafas - France

Raffaella Giavazzi - Italy

Nina Iversen - Norway

Luis Jara-Palomares - Spain

Ajay J. Kakkar - UK

Michails V. Karamouzis - Greece

Barry Kevane - Ireland

Alok A. Khorana - USA

Cliona C. Kirwan - UK

Nicole Kuderer - USA

Roberto Labianca - Italy

Mandy N. Lauw - The Netherlands

Maria Luisa Lavitrano - Italy

Avi Leader - Israel

Agnes Y.Y. Lee - Canada

Marcel M. Levi - UK

Howard A. Liebman - USA

Simon Mantha - USA

Marina Marchetti - Italy

Norma Maugeri - Italy

Keith McCrae - USA

Florian Moik - Austria

Manuel B. Monreal - Spain

Frits Mulder - The Netherlands

Andrés J. Muñoz Martín - Spain

Mariasanta Napolitano - Italy

Simon Noble - UK

Jamie Marie O'Sullivan - Ireland

Anne-Karin Olsson - Sweden

Ingrid Pabinger - Austria

Joseph S. Palumbo - USA

Laurence Panicot-Dubois - France

Marina Panova-Noeva - Germany

Bianca Rocca - Italy

Axel Rosell - Sweden

Elena Rossi - Italy

Wolfram Ruf - Germany

Per Morten Sandset - Norway

Kristen M. Sanfilippo - USA

Francesca Schieppati - Italy

Rita Selby - Canada

Giulia Taraboletti - Italy

Hugo ten Cate - The Netherlands

Arina J. ten Cate-Hoek - The Netherlands

Alexandros D. Tselepis - Greece

Antonella Tufano - Italy

Nick Van Es - The Netherlands

Tzu-Fei Wang - Canada

Ilene C. Weitz - USA

Eilam Yeini - Israel

Annie Young - UK

Jeffrey I. Zwicker - USA

SCIENTIFIC PROGRAM

Friday, May 27th 2022

Oggioni Room - Ground Floor

- 8:15 - 08:30 **Opening remarks from the Conference Chairman**
Anna Falanga, Benjamin Brenner, Alok A. Khorana
- 8:30 - 10:45 **PLENARY SESSION 1**
Emerging trends in cancer associated thrombosis
Chairs: Per Morten Sandset (Norway), Rita Selby (Canada)
- 8:35 - 9:00 **VTE in cancer in contemporary era** PL - 01
Frits Mulder (The Netherlands)
- 9:00 - 9:25 **Contemporary breast cancer treatment-associated thrombosis** PL - 02
Cliona C. Kirwan (UK)
- 9:25 - 9:50 **Machine learning for risk stratification of CAT** PL - 03
Grigoris T. Gerotziafas (France)
- 9:50 - 10:15 **Venous thromboembolism and risk stratification in hematological malignancies** PL - 04
Kristen M. Sanfilippo (USA)
- 10:15 - 10:30 **Selected abstract**
- 10:15 - 10:30 **Mortality impact of cancer-associated venous thromboembolism: final analysis from Oncothromb12-01 study** OC - 01
M. Ruiz, A.J. Muñoz Martín, C. Font, V. Castellón, M. Salgado, E. Martínez, A. Rupérez, A. Cárdenas, R. Martín-Lozano, I. González-Caraballo, R. Jiménez, L. Ortega, E. Salas, J.M Soria (Spain)
- 10:30 - 10:45 **Outcomes of cancer-associated isolated superficial vein thrombosis in daily practice** OC - 02
F. Langer, H.E. Gerlach, A. Schimke, A. Heinken, U. Hoffmann, T. Noppeney, D. Pittrow, J. Klotsche, E. Rabe, R.M. Bauersachs (Germany)
- 10:45 - 11:15 Coffee Break

SCIENTIFIC PROGRAM

11:15 - 13:30

PLENARY SESSION 2

Exploring the relationship between hemostasis and cancer: new insights

Chairs: Anne-Karin Olsson (Sweden), Raffaella Giavazzi (Italy)

11:20 - 11:45

P-Selectin as an emerging target for cancer therapy

Eilam Yeini (Israel)

PL - 05

11:45 - 12:10

Cancer genetic alterations and risk of venous thromboembolism

Simon Mantha (USA)

PL - 06

12:10 - 12:35

The role of neutrophil extracellular traps in cancer-associated thrombosis

Axel Rosell (Sweden)

PL - 07

12:35 - 13:00

Role and regulation of TFPI and FV in tumor cells

Nina Iversen (Norway)

PL - 08

Selected abstract

13:00 - 13:15

Platelet-derived von Willebrand factor is involved in thrombosis and metastatic growth of melanoma in the brain

S.W. Schneider, J.R. Robador, F. T. Mayer, M. Feinauer, L. Keller, K. Pantel, J. Stadler, C. Gorzelanny, F. Winkler, and A.T. Bauer (Germany)

OC - 03

13:15 - 13:30

Neutrophil extracellular traps promote cancer-associated inflammation and myocardial stress

J. Cedervall, M. Herre, A. Dragomir, F. Rabelo-Melo, A. Svensson, C. Thålin, A. Rosell, V. Hjalmar, H. Wallén, H. Lindman, G. Pejler, E. Hagström, M. Hultström, A. Larsson, A.K. Olsson (Sweden)

OC - 04

13:30 - 14:30

LUNCH SPECIAL LECTURE

Chair: Anna Falanga (Italy)

Importance of biobanking in cancer and thrombosis research: building new 'horizons'

Maria Luisa Lavitrano (Italy)

14:30 - 15:00

Coffee and pastries

SCIENTIFIC PROGRAM

- 15:00 - 17:30 **PLENARY SESSION 3**
Role of hemostatic biomarkers in CAT and cancer progression
Chairs: Cihan Ay (Austria), Barry Kevane (Ireland)
- 15:05 - 15:30 **Bi-directional cross talk between coagulation and cancers: current assessment of pre-clinical evidence** PL - 09
Jamie Marie O'Sullivan (Ireland)
- 15:30 - 15:55 **PET scan for occult cancer among patients with unprovoked VTE: what do we know?** PL - 10
Aurélien Delluc (Canada)
- 15:55 - 16:20 **The relationship between platelets and cancer cells in the growing thrombus and in the development of cancer** PL - 11
Laurence Panicot-Dubois (France)
- 16:20 - 16:45 **Hemostatic system activation in breast cancer: searching for new biomarkers of cancer outcome** PL - 12
Marina Marchetti (Italy)
- 16:45 - 17:00 **Selected abstract**
Thromboembolism after Incident Colorectal Cancer in the Netherlands: Incidence, Predictors, and Prognosis OC-05
R.J.S. Anijs, Q. Chen, W.M. Lijfering, S.C. Cannegieter (The Netherlands)
- 17:00 - 17:15 **Identification of predictive hemostatic biomarkers for cancer diagnosis: results from the HYPERCAN study** OC-06
S. Gamba, M. Marchetti, L. Russo, C. Giaccherini, S. Bolognini, C. J. Tartari, C. Verzeroli, C. Ticozzi, A. Vignoli, F. Schieppati, G. Sampietro, P. Malighetti, D. Spinelli, A. Falanga (Italy)
- 17:15 - 17:30 **Contact pathway activation and risk of venous thromboembolism in patients with pancreatic cancer: the prospective SENECA study** OC-07
F.T.M. Bosch, E. Campello, M.W. Henderson, F.I. Mulder, S. Gavasso, C. Bassi, J.W. Wilmink, H.M. Otten, N. van Es, A. Ilich, N. Key, H.R. Büller, P. Simioni (The Netherlands, USA, Italy)
- 17:30 - 18:00 Tea Break

SCIENTIFIC PROGRAM

18:00 - 19:00

DEBATE

Catheter-associated Thrombosis in cancer patients: to prophylax or not to prophylax?

Chairs: Benjamin Brenner (Israel), Elena Faioni (Italy)

YES: Marc Carrier (Canada)

NO: Luis Jara-Palomares (Spain)

19:00 - 20:00

PLENARY LECTURE

7th Simon Karpatkin Memorial Lecture

Chairs: Anna Falanga (Italy), Benjamin Brenner (Israel), Alok A. Khorana (USA)

Introduction to Lecture

Alok A. Khorana (USA)

Crosstalk between hemostasis and immunity in cancer pathogenesis

Joe S. Palumbo (USA)

20:00 - 21:00

Welcome reception

SCIENTIFIC PROGRAM

Saturday, May 28th 2022

Oggioni Room - Ground Floor

8:30 - 10:45

PLENARY SESSION 4

Hemostatic complications and novel anti-cancer therapies

Chairs: Ilene C. Weitz (USA), Wolfram Ruf (Germany)

8:35 - 9:00

Old is new again: emergence of thromboembolic complications in cancer patients on immunotherapy

Keith McCrae (USA)

PL - 13

9:00 - 9:25

Venous and arterial thromboembolism in patients with cancer treated with targeted anti-cancer treatments

Florian Moik (Austria)

PL - 14

9:25 - 9:50

Drug-drug interactions: implications for anticoagulation use in patients with cancer

Tzu-Fei Wang (Canada)

PL - 15

9:50 - 10:15

Bleeding risk with direct oral anticoagulants in cancer patients

Rupert M. Bauersachs (Germany)

PL - 16

Selected abstract

10:15 - 10:30

The Khorana score and risk of venous thromboembolism in patients with cancer treated with immune checkpoint inhibitors

T.F. Overvad, A.G. Ording, P.B. Nielsen, G. Piazza, S. Noble, T.B. Larsen, F. Skjøth (UK)

OC-08

10:30 - 10:45

Rivaroxaban compared to no treatment in early breast cancer patients (the TIP Trial): initial findings for a phase II preoperative window-of-opportunity randomized controlled trial

C.C. Kirwan, J. Castle, S.A. Pritchard, N.J. Bundred, J Thachill, J.R. Harvey, P.G. Roy, A. Volleamere, E. Blower, C. Palmieri, B. Hogan, R. Vinayagam, K. Cox, A. Marshall, L. Turner, G. Gibson, H. Scott, C. Holcombe (UK)

OC-09

SCIENTIFIC PROGRAM

- 10:45 - 11:15 Coffee break
- 11:15 - 13:30 **PLENARY SESSION 5**
COVID-19, thrombosis and cancer
Chairs: Valerio De Stefano (Italy), Howard A. Liebman (USA)
- 11:20 - 11:45 **Cancer and COVID-19: where are the data?** PL - 17
Nicole Kuderer (USA)
- 11:45 - 12:10 **COVID-19 associated coagulopathy and thrombosis in cancer** PL - 18
Marcel M. Levi (UK)
- 12:10 - 12:35 **COVID-19 impact on thrombosis in hematological malignancies** PL - 19
Mandy N. Lauw (The Netherlands)
- 12:35 - 13:00 **Vaccine-induced immune thrombotic thrombocytopenia and patients with cancer** PL - 20
Jean M. Connors (USA)
- 13:00 - 13:15 **Selected abstract**
- 13:00 - 13:15 **Plasmatic von Willebrand factor encapsulates blood circulating melanoma cells to prevent their hematogenous metastasis** OC-10
Y. Wang, X. Liu, T. Obser, A.T. Bauer, M. Kusche-Gullberg, S. W. Schneider, C. Gorzelanny (Norway)
- 13:15 - 13:30 **Safety and efficacy of apixaban as thromboprophylaxis in multiple myeloma patients receiving chemotherapy: a prospective cohort study** OC-11
Z. Sayar, C. Gates, S. Bristogiannis, A. Patel, M.O. Ogunbiyi, A. Tailor, K. Yong, M. Thomas (UK)
- 13:30 - 14:30 **Satellite Symposia** (see pages 30-31)
Oggioni, Bianca and Alabastro rooms
- 14:30 - 15:00 Coffee and pastries

SCIENTIFIC PROGRAM

15:00 - 16:00

POSTER DISCUSSION SESSIONS 1-4

(see pages 17-20)

Poster Session 1: Biomarkers/Hypercoagulability I

Bianca Room

Chair: Elisabetta Castoldi (the Netherlands)

Poster Session 2: Bleeding complications

Oggioni Room

Chair: Erica De Candia (Italy)

Poster Session 3: Epidemiology

Alabastro Room

Chair: Marina Panova-Noeva (Germany)

Poster Session 4: Hemostatic proteins and cancer biology

Novelli Room

Chair: Giulia Taraboletti (Italy)

16:00 - 17:00

POSTER DISCUSSION SESSIONS 5-8

(see pages 21-24)

Poster Session 5: Therapeutic challenges

Oggioni Room

Chair: Mariasanta Napolitano (Italy)

Poster Session 6: Thromboprophylaxis and thrombotic risk assessment

Novelli Room

Chair: Francesca Schieppati (Italy)

Poster Session 7: Biomarkers/Hypercoagulability II

Bianca Room

Chair: Norma Maugeri (Italy)

Poster Session 8: Treatment of thrombosis in cancer

Alabastro Room

Chair: Elena Rossi (Italy)

17:00 - 18:30

ROUNDTABLE

Multidisciplinary approach in cardiovascular oncology

Chairs: Arina ten Cate-Hoek (The Netherlands),
Ingrid Pabinger (Austria)

Introduction: building a CAT clinic - real-world systems approaches to prevention and treatment

Alok A. Khorana (USA)

Discussants: Benjamin Brenner (Israel), Ajay J. Kakkar (UK),
Nick van Es (The Netherlands), Ismail Elalamy (France),
Andrés J. Muñoz Martín (Spain), Manuel B. Monreal (Spain)

SCIENTIFIC PROGRAM

Sunday, May 29th 2022

Oggioni Room - Ground Floor

8:30 - 10:45

PLENARY SESSION 6

Cardiovascular complications in cancer patients

Chairs: Pantep Angchaisuksiri (Thailand), Bianca Rocca (Italy)

8:35 - 9:00

Evolving data on cardiovascular complications in cancer

Hugo Ten Cate (The Netherlands)

PL - 21

9:00 - 9:25

Cardiotoxic effects of antitumor agents: pathogenetic mechanisms

Alexandros D. Tselepis (Greece)

PL - 22

9:25 - 9:50

Optimizing antithrombotic therapy for atrial fibrillation in cancer

Antonella Tufano (Italy)

PL - 23

9:50 - 10:15

Clonal hematopoiesis and cardiovascular complications in cancer patients and survivors

Josè J. Fuster (Spain)

PL - 24

Selected abstract

10:15 - 10:30

Stroke and risk of cancer: a danish population-based cohort study

N. Skajaa, K. Veres, F.S. Troelsen, J.D. Petersen,
K. Adelborg, H.T. Sørensen (Denmark)

OC-12

10:30 - 10:45

Differentially expressed coagulome genes (DECGs) are prognostic in breast cancer

M. Tinholt, X. Tekpli, V. Kristensen, P.M. Sandset, N. Iversen (Norway)

OC-13

10:45 - 11:45

DEBATE

Duration of VTE treatment beyond 6 months: to continue or not to continue?

Chairs: Alexander Cohen (UK), Suzanne C. Cannegieter (NL)

YES: Agnes Y.Y. Lee (Canada)

NO: Marcello Di Nisio (Italy)

SCIENTIFIC PROGRAM

11:45 - 12:45	Brunch	
12:45 - 15:40	<u>PLENARY SESSION 7</u> Prevention and treatment of cancer-associated thromboembolism Chairs: Roberto Labianca (Italy), Annie Young (UK)	
12:50 - 13:15	Prevent and treat VTE in cancer patients: ESMO guidelines Anna Falanga (Italy)	PL - 25
13:15 - 13:40	The impact of warfarin on overall survival in cancer patients with VTE Jeffrey I. Zwicker (USA)	PL - 26
13:40 - 14:05	The impact of thromboprophylaxis on the survival of patients with pancreatic cancer Michails Karamouzis (Greece)	PL - 27
14:05 - 14:30	Cancer-associated non-bacterial thrombotic endocarditis Avi Leader (Israel)	PL - 28
14:30 - 14:55	Risk benefit analysis of anticoagulation in elderly cancer patients Simon Noble (UK)	PL - 29
14:55 - 15:10	Selected abstract Effectiveness and safety of 6-months' treatment with different full-dose enoxaparin regimens in patients with cancer-associated venous thromboembolism: a subgroup analysis of the RIETECAT cohort study <u>M.B. Monreal</u> , L. Bertoletti, J. J. López-Núñez, G. Tiberio, S. Soler, C. Gómez-Cuervo, Á. Fidalgo, M. Mellado, P. López-Miguel, J. A. Díaz-Peromingo, the RIETE Investigators (France, Spain)	OC-14
15:10 - 15:25	Targeted thromboprophylaxis in ambulatory patients receiving anticancer therapies for lung or gastrointestinal cancers (TARGET-TP); a randomized trial M. Alexander, S.J. Harris, C. Underhill, J.Torres, S.Sharma, N. Lee, H. Wong, R. Eek, M. Michael, J. Tie, J. Rogers, A. Heriot, D. Ball, M. MacManus, R. Wolfe, B. Solomon, <u>K. Burbury</u> (Australia)	OC-15

SCIENTIFIC PROGRAM

15:25 - 15.40 **Comparison of VTE recurrence, bleeding-related hospitalization and all-cause mortality in patients with active cancer in two patient populations, based upon cancer types considered to have high and low risks of bleeding, receiving DOACs or LMWH – The OSCAR UK Study**

OC-16

A.T. Cohen, C. Wallenhorst, C. Ay, B. Schaefer, K. Abdelgawwad, G. Psaroudakis, G. Brobert, C. I. Coleman, A. Ekbom, A.Y.Y. Lee, A. Khorana, C. Becattini, M. Carrier, M. Rivera, C. Martinez (UK, Germany, USA, Sweden, Canada)

15:40

Concluding Remarks

Anna Falanga, Benjamin Brenner, Alok A. Khorana

POSTER DISCUSSION SESSIONS

Saturday 28th

15:00 – 16:00

Poster Session I

Bianca Room - 1st Floor

Biomarkers/Hypercoagulability I

Chair: Elisabetta Castoldi (the Netherlands)

- PO-01 KRAS mutation in colorectal cancer and risk of venous thromboembolism: a Danish population-based cohort study**
F.S. Troelsen, E.K. Vágó, E. Horváth-Puhó, N. van Es, F. Mulder, F. Moik, R. Erichsen, C. Ay, H.T. Sørensen
- PO-02 Monocyte recruitment in venous pulmonary embolism at time of cancer diagnosis in upper GI cancer patients**
S.S. Jakobsen, J.B. Frøkjær, R.V. Fisker, S.R. Kristensen, O. Thorlacius-Ussing, A.C. Larsen
- PO-03 Antithrombin activity and association with risk of thrombosis and mortality in patients with cancer**
C. Englisch, O. Königsbrügge, F. Moik, P. Quehenberger, M. Preusser, I. Pabinger, C. Ay
- PO-04 Thrombin generation and D-dimer significantly predict for early disease progression and mortality in patients with gastrointestinal cancer**
C. Giaccherini, M. Marchetti, C. Verzeroli, L. Russo, S. Gamba, C. J. Tartari, S. Bolognini, C. Ticozzi, F. Schieppati, A. Santoro, F. De Braud, G. Gasparini, F. Petrelli, F. Giuliani, A. D'Alessio, M. Minelli, R. Labianca, C. Morlotti, P. Malighetti, D. Spinelli, A. Falanga, on behalf of the HYPERCAN Investigators
- PO-05 D-dimers cut off level to predict the risk of venous thromboembolism in newly diagnosed multiple myeloma**
S. Charles, A. Chaudier, T. Fatrara, E. Dagueneu, L. Karlin, A. Montmartin, K. Boussoulim, B. Tardy-Poncet, B. Tardy, T. Lecompte, D. Guyotat, E. Chalayer
- PO-06 Thrombomodulin as a marker for VTE following neoadjuvant chemotherapy**
M.P. Ward, E. Ibrahim, S. O'Toole, N. Gleeson, F. Abu Saadeh, D. O'Donnell, L.A. Norris
- PO-07 Procoagulant extracellular vesicles in patients with different types of acute leukemia**
Y. Hisada, S. J. Archibald, K. Bansal, S. Dwarampudi, A.K. Mullen, S. Bhatia, R. Bhatia, N. Mackman, R. Gangaraju
- PO-08 Characterisation of plasma extracellular vesicles in myeloproliferative neoplasms**
S. Kelliher, H. Macleod, L. Weiss, P.B. Szklanna, S. Gamba, F. Ní Áinle, F. Schieppati, M. Marchetti, P.B. Maguire, A. Falanga, B. Kevane

POSTER DISCUSSION SESSIONS

15:00 – 16:00

Poster Session II

Oggioni Room - Ground Floor

Bleeding complications

Chair: Erica De Candia (Italy)

- PO-09 Risk of intracranial hemorrhage of Direct Oral Anticoagulants (DOACs) versus Low Molecular Weight Heparin (LMWH) in brain cancers: a meta-analysis of comparative studies**
P. Haddad, D. Hammoud, K. Gallagher
- PO-10 Rate of thrombosis and bleeding after urological surgery under standardized anticoagulation**
J. Cordes
- PO-11 Risk of major bleeding in cancer patients with ischemic stroke treated with thrombolysis**
N. Skajaa, K. Adelborg, F. Schønfeldt Troelsen, C. Hvitfeldt Fuglsang, E. Horváth-Puhó, H. Toft Sørensen
- PO-12 Risk of bleeding after surgery for colorectal cancer in type 2 diabetes patients: a Danish population-based cohort study**
F.P. Kristensen, S.K. Szépligeti, F.S. Troelsen, H.T. Sørensen
- PO-13 Lower-extremity deep vein thrombosis and bleeding complications in primary brain tumor patients: a prospective study**
V. Muster, R.B. Raggam, T. Urbanic-Purkart, F. Posch, K. Gütl, J. Rabensteiner, F. Prüller, G. von Campe, M. Rief, M. Brodmann, T. Gary
- PO-14 Real-world data. Incidence of venous thromboembolism recurrence and bleeding among cancer patients**
D.C. Silva-Cardenas, F. Pikabea-Diaz, A. Zumarraga-Cuesta, M. Lopez-Santillan, C. Figaredo-Berjano, P.L. Loaiza-Jaramillo, P. Casado-Cuesta, M. Temiño-Frances, B. Lopez-de-San-Vicente-Hernandez, E. Novo-Sukia, J. Legaspi-Folgueira, J.R. Barcelo-Galindez, L. Sande-Sardina, M. Nuño-Escolastico, M.T. Abad-Villar, M.A. Sala-Gonzalez, E. Galve-Calvo, M.P. Martinez-del-Prado
- PO-15 Tinzaparin: a safe choice for cancer Lung cancer with VTE and renal impairment**
E. Dimakakos, N. Syrigos, I. Vathiotis, K. Tsiakos, M. Anagnostakis, M. Grammoustianou, G. Gomatou, F. Sarropoulou, G.T. Gerotziapas, E. Kotteas

POSTER DISCUSSION SESSIONS

15:00 – 16:00

Poster Session III

Alabastro Room - 2nd Floor

Epidemiology

Chair: Marina Panova-Noeva (Germany)

- PO-16 Prevalence of thrombocytopenia in patients with acute cancer-associated thrombosis**
C. Hsu, R. Patell, J. I. Zwicker
- PO-17 Socioeconomic position and the risk of occult cancer in venous thromboembolism**
H. Jørgensen, E. Horváth-Puhó, K. Laugesen, S. Brækkan, JB. Hansen, H.T. Sørensen
- PO-18 Myocardial infarction and risk of cancer**
J.D. Petersen, K. Veres, F.S. Troelsen, N. Skajaa, K. Adelborg, H.T. Sørensen
- PO-19 Venous and arterial thromboembolism in pancreatic neuroendocrine neoplasms**
L. Gervaso, A. Laffi, M.I. Meneses-Medina, C.A. Cella, M. Rubino, S. Pellicori, F. Spada, N. Fazio
- PO-20 Incidence of venous thromboembolism in patients with braf-mutated colorectal cancer**
L. Ortega Morán, D. Pesántez, E. Brozos Vázquez, D. Fernández Garay, M. Lobo de Mena, P. Ribera Fernández, M. Sánchez Cánovas, M. Salgado, E. García Pérez, E. Iriarte Moncho, B. Morón García, C. Font, E. Gallardo, J. Pérez Altozano, Andrés Muñoz Martín
- PO-21 PICC vs. Port in patients with hematologic malignancies**
N. Pérez Fidalgo, M. Marcos-Jubilar, C. Guillén, R. Figueroa, M.L. Palacios, S. Huerga, M. Panizo, J.A. Páramo, R. Lecumberri
- PO-22 Rate of Venous thromboembolism events in cancer patients treated by radiation therapy: the Radiation-Induced Thrombosis study**
E. Daguinet, M. Maison, F. Tinquaut, E-A. Giroux, L. Bertoletti, J.-P. Suchaud, C. Rancoule, J.-B. Guy, N. Magné
- PO-23 Upper Extremity Deep Vein Thrombosis in cancer patients: our experience**
S. Mangiacapra, F. Cannavacciuolo, M. Nunziata, M. Raimondo, V. Iorio, N. Iuliano, M. Amitrano
- PO-24 Incidence of venous thromboembolism following head and neck surgery stratified according to cancer: a Danish nation-wide cohort study**
I.E. Albertsen, N.M. Lyhne, T.B. Larsen, P.B. Nielsen

POSTER DISCUSSION SESSIONS

15:00 – 16:00

Poster Session IV

Novelli Room - 2nd Floor

Hemostatic proteins and cancer biology

Chair: Giulia Taraboletti (Italy)

- PO-25** Elevated plasma von Willebrand Factor in patients with breast cancer may contribute to the early metastatic niche, promoting endothelial adhesion, invasion and angiogenic properties of circulating breast cancer cells
S. Patmore, S.P.S. Dhami, C. Comerford, J. Castle, C.C. Kirwan, J.S. O'Donnell, J.M. O'Sullivan
- PO-26** Development of a spontaneous model for cancer-associated thrombosis
B. Ünlü, M. Heestermans, El Houari Laghmani, J.T. Buijs, B.J.M. van Vlijmen, H.H. Versteeg
- PO-27** Platelet-cancer cell hetero-aggregate formation is sustained by fibrin polymerization initiated on the cancer cell surface, and platelet entrapment into the fibrin network
I.P. Tesakov, A.A. Filkova, A.A. Deputatova, A.D. Korneichuk, A.A. Martyanov, M.A. Pantelev, A.N. Sveshnikova
- PO-28** Investigating the relationship between a stromal wound healing phenotype and breast density as a mechanism for breast cancer development
H. Ogunlayi, J. Castle, R.B. Clarke, A. Armstrong, C.C. Kirwan
- PO-29** Coagulation and Circulating Tumour Cells as pharmacodynamic biomarkers of response to aromatase inhibitors in breast cancer
C.C. Kirwan, J. Castle, S. Pritchard, H. Tovey, N.J. Bundred, I. Smith, J. Robertson, J. Bliss, M. Dowsett
- PO-30** Chemotherapeutic agents Temozolomide and Lomustine induce procoagulant activity of glioblastoma cell lines in vitro
M.Y. Kapteijn, S. Zwaan, E. ter Linden, R.F.P. van den Akker, A.M. Rocha Rondon, H.H. Versteeg, J.T. Buijs
- PO-31** The small-molecule FXIa inhibitor, BMS-262084, prevents tumor cell-induced coagulation activation predominantly in tumor entities with lower tissue factor (TF) expression
J. Mäder, M. Voigtlaender, C. Rolling, H. Quick, A. Schulenkorf, C. Lehr, C. Bokemeyer, L. Beckmann, F. Langer
- PO-32** Rivaroxaban targets the hypercoagulant tumour microenvironment to reduce primary tumour growth and stem cell activity in oestrogen receptor positive breast cancer murine models
E.L. Blower, J. Castle, A. Santiago-Gomez, R.B. Clarke, C.C. Kirwan

POSTER DISCUSSION SESSIONS

16:00 – 17:00

Poster Session V

Oggioni Room - Ground Floor

Therapeutic challenges

Chair: Mariasanta Napolitano (Italy)

- PO-33 Real-world VTE and implemented treatments in patients with cancer: an observational study in the French EGB database**
I. Mahé, D. Mayeur, C. Chouaid, J.L. Gaudry, M. Foist, D. Pertus, N. Spiess
- PO-34 Antiplatelet and cytostatic properties of Nilotinib synthetic analogues**
L.M. Pechlivani, N. Ntemou, P. Voulgari, D. Pantazi, K. Skobridis, A.D. Tselepis
- PO-35 A method for prioritisation and translation of pleiotropic effects into clinical applications: lessons from low molecular weight heparin treatment in cancer**
A. Heald, M. Davies, P. Riley
- PO-36 The impact of oral anticoagulant drugs for arterial thromboembolism in patients with cancer**
A. Foresta, P. Colacioppo, M. Baviera, L. Ojeda-Fernandez, C. Cimminiello
- PO-37 A study of the evolution of radiological features of untreated small volume pulmonary embolism (PE) in cancer patients**
E. Haque, N. Jawad, A. Brzuszek, R. Birk, A. Stephens, V. Brown, G. Bozas, G. Avery, A. Maraveyas
- PO-38 A new armamentarium choice in cancer-associated upper-limb vein thrombosis resistant to heparin: a clinical case of seminoma in bep chemotherapy protocol solved with edoxaban**
A.M. Fioretti, T. Leopizzi, F. Giotta, V. Lorusso, G. Luzzi, S. Oliva
- PO-39 Superior vena cava stenting: an effective and safe therapeutic choice for the treatment of Superior Vena Cava Syndrome in lung cancer patients**
M. Grammoustianou, N. Syrigos, F. Sarropoulou, V. Patriarcheas, N. Ptohis, A. Charpidou, I. Gkiozos, M. Kouvela, G.T. Gerotziafas, E. Kainis, El. Kotteas, E. Dimakakos
- PO-40 Therapeutic Approaches of Superior Vena Cava Syndrome in patients with Non-Small Cell Lung Cancer (NSCLC)**
E. Dimakakos, M. Grammoustianou, F. Sarropoulou, M. Kouvela, I. Gkiozos, E. Kotteas, G.T. Gerotziafas, D. Mavroudis, K.N. Syrigos
- PO-41 Cancer Associated Thrombosis: how many patients seen in clinical practice would be eligible to a randomized controlled trial?**
B. Petit, S. Soudet, G. Poenou, E. Zarrat, T. Machuron, S. Accassat, L. Plaisance, H. Helfer, V. Mismetti, C. Le Hello, M-A. Sevestre, I. Mahé, L. Bertoletti

POSTER DISCUSSION SESSIONS

16:00 – 17:00

Poster Session VI

Novelli Room - 2nd Floor

Thromboprophylaxis and thrombotic risk assessment

Chair: Francesca Schieppati (Italy)

- PO-42 Cancer-associated Thrombosis (CAT): To which extend are cancer patients educated about their increased risk, and which factors determine if prophylaxis is realized – results of a patients' survey**
J. Kranefeld, A. Schirmer, S. Hessler, A. Schmidt
- PO-43 Pharmacological thromboprophylaxis to prevent venous thromboembolism in ambulatory patients with cancer undergoing antineoplastic drugs in real world clinical practice: a cohort study**
M.P. Donadini, A. Squizzato, P. Ferrazzi, S. Maggioni, C. Sacco, C. Lodigiani
- PO-44 Risk assessment model potency to detect patients most likely to benefit from thromboprophylaxis – an application of the TARGET-TP score**
M. Alexander, S.J. Harris, C. Underhill, J. Torres, S. Sharma, N. Lee, H. Wong, R. Eek, M. Michael, J. Tie, J. Rogers, A. Heriot, D. Ball, M. MacManus, R. Wolfe, B. Solomon, K. Burbury
- PO-45 Cancer Associated Thrombosis (CAT) in Gynecological Cancers: data from ACT4CAT study**
N. Tsoukalas, A. Christopoulou, E. Timotheadou, I. Athanasiadis, A. Koumariou, S. Peroukidis, G. Samelis, A. Psyrris, N. Kapodistrias, A. Nikolakopoulos, C. Andreadis, A. Ardavanis, E. Samantas, C. Papandreou, D. Mavroudis, A. Bokas, V. Barbounis, N. Kentepozidis, A. Athanasiadis, P. Papakotoulas, I. Boukovinas
- PO-46 Perception of the risk of thrombosis in clinicians treating patients with multiple myeloma**
M. Marcos-Jubilar, S. Huerga, M.L. Palacios, C. Guillén, R. Figueroa, J.A. Páramo, R. Lecumberri
- PO-47 Prevention and Treatment of recurrent thrombosis after reconstruction of major vessels**
C. Victor, B. Bogdan, K. Konstantin

POSTER DISCUSSION SESSIONS

16:00 – 17:00

Poster Session VII

Bianca Room - 1st Floor

Biomarkers/Hypercoagulability II

Chair: Norma Maugeri (Italy)

- PO-48 Coagulopathy in multiple myeloma**
K. Chasakova, L. Slavík, D. Starostka, J. Úlehlová, T. Papajík, J. Minařík
- PO-49 Genomic determinants and clinical relevance of cancer-associated thrombosis in biliary tract cancers**
L. Provenzano, D. Miliziano, F. Nichetti, C. Sposetti, C. Pircher, M. Bini, A. Franza, G. Massa, M. Niger, M. Di Bartolomeo, F. de Braud
- PO-50 Molecular landscape of the coagulome of oral squamous cell carcinoma**
M. Lottin, S. Soudet, M.-A. Sevestre, Z. Saidak, A. Galmiche
- PO-51 Kaposiform hemangioendothelioma is associated with platelet functional abnormalities that persist in patients even after complete blood cell count recovery**
I.P. Tesakov, A.A. Martyanov, O.I. An, A.A. Ignatova, G.S. Svidelskaya, J.J.D. Korobkin, G.A. Novichkova, M.A. Pantelev, L.A. Khachatryan, E.A. Sveshnikova
- PO-52 Neutrophil tissue factor is increased in Essential Thrombocythemia**
B.N. Reeves, S. Ghosh, K.J. Wilson, N.S. Key, R Pawlinski
- PO-53 Prostate cancer and the increased risk of deep vein thrombosis-case report**
M. Shorova, N. Jovanova, D. Stambolieva, S. Ortakovska, E. Velkova, E. Petkovic, R. Grubovic
- PO-54 Preliminary evaluation of venous thromboembolic risk in patients with colorectal cancer from the Cartago study**
M. Salgado, R. Molina, E. Brozos, E. Martínez, E. Cillán, T. Fullana, J.C. Villa, M. Lobo, M. Masvidal, R. Porta, B. Campos, F. Garicano, M Pàmols, I. Fernández, C. Font, P. Martínez, D. Gutiérrez, E. Horvath, A.L. Costa, M. Malheiro, D. Arias, CARTAGO study group

POSTER DISCUSSION SESSIONS

16:00 – 17:00

Poster Session VIII

Alabastro Room - 2nd Floor

Treatment of thrombosis in cancer

Chair: Elena Rossi (Italy)

- PO-55 Effectiveness and safety of enoxaparin in the extended treatment of venous thromboembolism in active cancer patients with renal impairment - Results from the RIETECAT-RI cohort study**
J.J. López-Núñez, J. Trujillo-Santos, L. Bertolletti, J.L. Lobo, A. Visonà, R. Otero, P. Ruiz-Sada, C. De Ancos, I. Mahé, [M.B. Monreal](#)
- PO-56 Low molecular weight heparin beyond 12 months in patients with cancer associated thrombosis. CAT-LONG study**
S. Lopez-Ruz, M. Barca-Hernando, S. Marin-Romero, M.T. Elias-Hernandez, R. Otero-Candelera, [L. Jara-Palomares](#)
- PO-57 Venous thromboembolism recurrence during anticoagulant treatment in gastrointestinal cancer patients**
[A.J. Muñoz Martín](#), R. Lecumberri, J.C. Souto, J. Aparicio, B. Obispo, A. Sanchez, C. Aguayo, D. Gutierrez, M.C. Viñuela-Benítez, S. Menke, H. Casero, D. Arumí, M.Á. Hernández-Presa
- PO-58 Cancer-Associated Venous Thromboembolism: the Onco-VTE START2 – Registry**
E. Antonucci, [L. Barcella](#), L. Russo, A. Chistolini, A. Serrao, G. Elmi, P. Sivera, A. Falanga, G. Palareti
- PO-59 Dealing with pediatric cancer associated thrombosis: a case report and a monocentric cohort study**
[E. Campello](#), A. Francavilla, M.F. Pelizza, S. Sebellin, M. Nosadini, J.N. Pin, G. Lorenzoni, A. Biffi, D. Gregori, C. Forestan, M. Martinato, S. Sartori, P. Simioni
- PO-60 Comparison of inferior vena cava (IVC) filter use and outcomes between cancer and non-cancer patients in a single-center cohort**
[N. Lopez](#), C. Zamora, M. Montoya, C. Gabara, M. Ortiz, J. Aibar
- PO-61 Direct Oral Anticoagulants (DOAC) in Cancer Associated Thrombosis (CAT) Experience of thrombosis clinic of Tertiary Cancer Institute**
[A. Daddi](#), S. Sawant, A. Alahari Dhir
- PO-62 Improves oral anticoagulation controls and quality of life in by remote control compared to traditional controls in oncological thrombosis in the pediatric population**
[R. Martos](#), L. Bermejo, M. Yuste, E. González, D. Cornejo, B. Villa, E. Herreros, P. Beltrán, P. Llamas
- PO-63 Edoxaban effect in a breast cancer patient with liver arterial infusion chemotherapy (laic) and both jugular vein and hepatic artery thrombosis: a unique clinical case**
[A.M. Fioretti](#), T. Leopizzi, M. Porcelli, V. Fazio, G. Ranieri, G. Luzzi, C.D. Gadaleta, S. Oliva

AUTHOR INDEX

A

Abad-Villar, M.T. PO-14
Abdelgawwad, K. OC-16
Abu Saadeh, F. PO-06
Accassat, S. PO-41
Adelborg, K. OC-12, PO-11, PO-18
Aguayo, C. PO-57
Aibar, J. PO-60
Alahari Dhir, A. PO-61
Albertsen, I.E. PO-24
Alexander, M. OC-15, PO-44
Amitrano, M. PO-23
An, O.I. PO-51
Anagnostakis, M. PO-15
Andreadis, C. PO-45
Anijs, R.J.S. OC-05
Antonucci, E. PO-58
Aparicio, J. PO-57
Archibald, S.J. PO-07
Ardavanis, A. PO-45
Arias, D. PO-54
Armstrong, A. PO-28
Arumí, D. PO-57
Athnasiadis, A. PO-45
Athnasiadis, I. PO-45
Avery, G. PO-37
Ay, C. OC-16, PO-01, PO-03

B

Ball, D. OC-15, PO-44
Bansal, K. PO-07
Barbounis, V. PO-45
Barca-Hernando, M. PO-56
Barcella, L. PO-58
Barcelo-Galindez, J.R. PO-14
Bassi, C. OC-07
Bauer, A.T. OC-03, OC-10
Bauersachs, R. PL-16, OC-02
Baviera, M. PO-36
Becattini, C. OC-16
Beckmann, L. PO-31
Beltrán, P. PO-62
Bermejo, L. PO-62

Bertoletti, L. OC-14, PO-22, PO-41, PO-55
Bhatia, R. PO-07
Bhatia, S. PO-07
Biffi, A. PO-59
Bini, M. PO-49
Birk, R. PO-37
Bliss, J. PO-29
Blower, E. OC-09, PO-32
Bogdan, B. PO-47
Bokas, A. PO-45
Bokemeyer, C. PO-31
Bolognini, S. OC-06, PO-04
Bosch, F.T.M. OC-07
Boukovinas, I. PO-45
Boussoualim, K. PO-05
Bozas, G. PO-37
Brækkan, S. PO-17
Brenner, B. RT
Bristogiannis, S. OC-11
Brobert, G. OC-16
Brodmann, M. PO-13
Brown, V. PO-37
Brozos Vázquez, E. PO-20, PO-54
Brzuszek, A. PO-37
Buijs, J.T. PO-26, PO-30
Büller, H.R. OC-07
Bundred, N.J. OC-09, PO-29
Burbury, K. OC-15, PO-44

C

Campello, E. OC-07, PO-59
Campos, B. PO-54
Cannavacciuolo, F. PO-23
Cannegieter, S.C. OC-05
Cárdenas, A. OC-01
Carrier, M. D1, OC-16
Casado-Cuesta, P. PO-14
Casero, H. PO-57
Castellón, V. OC-01
Castle, J. OC-09, PO-25, PO-28, PO-29, PO-32
Cedervall, J. OC-04

Cella, C.A. PO-19
Chalayer, E. PO-05
Charles, S. PO-05
Charpidou, A. PO-39
Chasakova, K. PO-48
Chaudier, A. PO-05
Chen, Q. OC-05
Chistolini, A. PO-58
Chouaid, C. PO-33
Christopoulou, A. PO-45
Cillán, E. PO-54
Cimminiello, C. PO-36
Clarke, R.B. PO-28, PO-32
Cohen, A.T. OC-16
Colacioppo, P. PO-36
Coleman, C.I. OC-16
Comeford, C. PO-25
Connors, J. M. PL-20
Cordes, J. PO-10
Cornejo, D. PO-62
Costa, A.L. PO-54
Cox, K. OC-09

D

D'Alessio, A. PO-04
Daddi, A. PO-61
Daguenet, E. PO-05, PO-22
Davies, M. PO-35
De Ancos, C. PO-55
De Braud, F. PO-04, PO-49
Delluc, A. PL-10
Deputatova, A.A. PO-27
Dhami, S.P.S. PO-25
Di Bartolomeo, M. PO-49
Di Nisio, M. D2
Díaz-Peromingo, J.A. OC-14
Dimakakos, E. PO-15, PO-39, PO-40
Donadini, M.P. PO-43
Dowsett, M. PO-29
Dragomir, A. OC-04
Dwarampudi, S. PO-07

E

Eek, R. OC-15, PO-44

AUTHOR INDEX

Ekboom, A. OC-16
Elalamy, I. RT
Elias-Hernandez, M.T. PO-56
Elmi, G. PO-58
Englisch, C. PO-03
Erichsen, R. PO-01

F

Falanga, A. PL-25, OC-06,
PO-04, PO-08, PO-58
Fatrara, T. PO-05
Fazio, N. PO-19
Fazio, V. PO-63
Feinauer, M. OC-03
Fernández Garay, D. PO-20
Fernández, I. PO-54
Ferrazzi, P. PO-43
Fidalgo, Á. OC-14
Figaredo-Berjano, C. PO-14
Figueroa, R. PO-21, PO-46
Filkova, A.A. PO-27
Fioretti, A.M. PO-38, PO-63
Fisker, R.V. PO-02
Foist, M. PO-33
Font, C. OC-01, PO-20, PO-54
Foresta, A. PO-36
Forestan, C. PO-59
Francavilla, A. PO-59
Franza, A. PO-49
Frøkjær, J.B. PO-02
Fullana, T. PO-54
Fuster, J.J. PL-24

G

Gabara, C. PO-60
Gadaleta, C.D. PO-63
Gallagher, K. PO-09
Gallardo, E. PO-20
Galmiche, A. PO-50
Galve-Calvo, E. PO-14
Gamba, S. OC-06, PO-04, PO-08
Gangaraju, R. PO-07
García Pérez, E. PO-20
Garicano, F. PO-54

Gary, T. PO-13
Gasparini, G. PO-04
Gates, C. OC-11
Gaudry, J.L. PO-33
Gavasso, S. OC-07
Gerlach, H.E. OC-02
Gerotziapas, G.T. PL-03, PO-15,
PO-39, PO-40
Gervaso, L. PO-19
Ghosh, S. PO-52
Giaccherini, C. OC-06, PO-04
Gibson, G. OC-09
Giotta, F. PO-38
Giroux, E.-A. PO-22
Giuliani, F. PO-04
Gkiozos, I. PO-39, PO-40
Gleeson, N. PO-06
Gomatou, G. PO-15
Gómez-Cuervo, C. OC-14
González, E. PO-62
González-Caraballo, I. OC-01
Gorzelanny, C. OC-03, OC-10
Grammoustianou, M. PO-15,
PO-39, PO-40
Gregori, D. PO-59
Grubovic, R. PO-53
Guillén, C. PO-21, PO-46
Gutierrez, D. PO-57
Gütl, K. PO-13
Guy, J.B. PO-22
Guyotat, D. PO-05

H

Haddad, P. PO-09
Hagström, E. OC-04
Hammoud, D. PO-09
Hansen, J.B. PO-17
Haque, F. PO-37
Harris, S.J. OC-15, PO-44
Harvey, J.R. OC-09
Heald, A. PO-35
Heestermans, M. PO-26
Heinken, A. OC-02
Helfer, H. PO-41

Henderson, M.W. OC-07
Heriot, A. OC-15, PO-44
Hernández-Presa, M. Á. PO-57
Herre, M. OC-04
Herreros, E. PO-62
Hessler, S. PO-42
Hisada, Y. PO-07
Hjalmar, V. OC-04
Hoffmann, U. OC-02
Hogan, B. OC-09
Holcombe, C. OC-09
Horváth-Puhó, E. PO-01,
PO-11, PO-17, PO-54
Hsu, C. PO-16
Huerga, S. PO-21, PO-46
Hultström, M. OC-04
Hvitfeldt Fuglsang, C. PO-11

I

Ibrahim, E. PO-06
Ignatova, A.A. PO-51
Ilich, A. OC-07
Iorio, V. PO-23
Iriarte Moncho, E. PO-20
Iuliano, N. PO-23
Iversen, N. PL-08, OC-13

J

Jakobsen, S.S. PO-02
Jara-Palomares, L. PO-56
Jawad, N. PO-37
Jiménez, R. OC-01
Jørgensen, H. PO-17
Jovanova, N. PO-53

K

Kainis, E.I. PO-39
Kakkar, A.J. RT
Kapodistrias, N. PO-45
Kapteijn, M.Y. PO-30
Karamouzis, M. PL-27
Karlin, L. PO-05
Keller, L. OC-03
Kelliher, S. PO-08

AUTHOR INDEX

Kentepozidis, N. PO-45
Kevane, B. PO-08
Key, N.S. OC-07, PO-52
Khachatryan, L.A. PO-51
Khorana, A.A. SKML,
RT, OC-16
Kirwan, C.C. PL-02, OC-09,
PO-25, PO-28, PO-29, PO-32
Klotsche, J. OC-02
Königsbrügge, O. PO-03
Konstantin, K. PO-47
Korneichuk, A.D. PO-27
Korobkin, J.J.D. PO-51
Kotteas, E.L. PO-15, PO-39,
PO-40
Koumarianou, A. PO-45
Kouvela, M. PO-39, PO-40
Kranefeld, J. PO-42
Kristensen, F.P. PO-12
Kristensen, S.R. PO-02
Kristensen, V. OC-13
Kuderer, N. PL-17
Kusche-Gullberg, M. OC-10

L

Labianca, R. PO-04
Laffi, A. PO-19
Laghmani, E.H. PO-26
Langer, F. OC-02, PO-31
Larsen, A.C. PO-02
Larsen, T.B. OC-08, PO-24
Larsson, A. OC-04
Laugesen, K. PO-17
Lauw, M.N. PL-19
Le Hello, C. PO-41
Leader, A. PL-28
Lecompte, T. PO-05
Lecumberri, R. PO-21, PO-46,
PO-57
Lee, A.YY. D2, OC-16
Lee, N. OC-15, PO-44
Legaspi-Folgueira, J. PO-14
Lehr, C. PO-31
Leopizzi, T. PO-38, PO-63

Levi, M. PL-18
Lijfering, W.M. OC-05
Lindman, H. OC-04
Liu, X. OC-10
Llamas, P. PO-62
Loaiza-Jaramillo, P.L. PO-14
Lobo de Mena, M. PO-20
Lobo, J.L. PO-55
Lobo, M. PO-54
Lodigiani, C. PO-43
Lopez, N. PO-60
Lopez-de-San-Vicente-
Hernandez, B. PO-14
López-Miguel, P. OC-14
López-Núñez, J.J. OC-14,
PO-55
Lopez-Ruz, S. PO-56
Lopez-Santillan, M. PO-14
Lorenzoni, G. PO-59
Lorusso, V. PO-38
Lottin, M. PO-50
Luzzi, G. PO-38, PO-63
Lyhne, N.M. PO-24

M

Machuron, T. PO-41
Mackman, N. PO-07
Macleod, H. PO-08
MacManus, M. OC-15, PO-44
Mäder, J. PO-31
Maggioni, S. PO-43
Magnè, N. PO-22
Maguire, P.B. PO-08
Mahé, I. PO-33, PO-41, PO-55
Maison, M. PO-22
Malheiro, M. PO-54
Malighetti, P. OC-06, PO-04
Mangiacapra, S. PO-23
Mantha, S. PL-06
Maraveyas, A. PO-37
Marchetti, M. PL-12, OC-06,
PO-04, PO-08
Marcos-Jubilar, M. PO-21,
PO-46

Marin-Romero, S. PO-56
Marshall, A. OC-09
Martinato, M. PO-59
Martinez, C. OC-16
Martínez, D. PO-54
Martínez, E. OC-01, PO-54
Martínez, P. PO-54
Martinez-del-Prado, M.P. PO-14
Martín-Lozano, R. OC-01
Martos, R. PO-62
Martyanov, A.A. PO-27, PO-51
Massa, G. PO-49
Masvidal, M. PO-54
Mavroudis, D. PO-40, PO-45
Mayer, F.T. OC-03
Mayer, D. PO-33
McCrae, K. PL-13
Mellado, M. OC-14
Meneses-Medina, M.I. PO-19
Menke, S. PO-57
Micheal, M. OC-15, PO-44
Minařík, J. PO-48
Minelli, M. PO-04
Mismetti, V. PO-41
Moik, F. PL-14, PO-01, PO-03
Molina, R. PO-54
Monreal, M.B. RT, OC-14, PO-55
Montmartin, A. PO-05
Montoya, M. PO-60
Morlotti, C. PO-04
Morón García, B. PO-20
Mulder, F. PL-01, PO-01, OC-07
Mullen, A.K. PO-07
Muñoz Martín, A.J. RT, OC-01,
PO-20, PO-57
Muster, V. PO-13

N

Ní Áinle, F. PO-08
Nichetti, F. PO-49
Nielsen, P.B. OC-08, PO-24
Niger, M. PO-49
Nikolakopoulos, A. PO-45
Noble, S. PL-29, OC-08

AUTHOR INDEX

Noppenev, T. OC-02
Norris, L.A. PO-06
Nosadini, M. PO-59
Novichkova, G.A. PO-51
Novo-Sukia, E. PO-14
Ntemou, N. PO-34
Nuño-Escolastico, M. PO-14
Nunziata, M. PO-23

O

O'Donnell, D. PO-06
O'Donnell, J.S. PO-25
O'Sullivan, J.M. PL-09, PO-25
O'Toole, S. PO-06
Obispo, B. PO-57
Obser, T. OC-10
Ogunbiyi, M.O. OC-11
Ogunlayi, H. PO-28
Ojeda-Fernandez, L. PO-36
Oliva, S. PO-38, PO-63
Olsson, A.K. OC-04
Ording, A.G. OC-08
Ortakovska, S. PO-53
Ortega Morán, L. OC-01, PO-20
Ortiz, M. PO-60
Otero, R. PO-55
Otero-Candelera, R. PO-56
Otten, H.M. OC-07
Overvad, T.F. OC-08

P

Pabinger, I. PO-03
Palacios, M.L. PO-21, PO-46
Palareti, G. PO-58
Palmieri, C. OC-09
Palumbo, J.S. SKML
Pàmpols, M. PO-54
Panicot-Dubois, L. PL-11
Panizo, M. PO-21
Pantazi, D. PO-34
Pantel, K. OC-03
Pantelev, M.A. PO-27, PO-51
Papajík, T. PO-48

Papakotoulas, P. PO-45
Papandreou, C. PO-45
Páramo, J.A. PO-21, PO-46
Patel, A. OC-11
Patell, R. PO-16
Patmore, S. PO-25
Patriarcheas, V. PO-39
Pawlinski, C. PO-52
Pechlivani, L.M. PO-34
Pejler, G. OC-04
Pelizza, M.F. PO-59
Pellicori, S. PO-19
Pérez Altozano, J. PO-20
Pérez Fidalgo, N. PO-21
Peroukidis, S. PO-45
Pertus, D. PO-33
Pesántez, D. PO-20
Petersen, J.D. OC-12, PO-18
Petit, B. PO-41
Petkovic, E. PO-53
Petrelli, F. PO-04
Piazza, G. OC-08
Pikabea-Diaz, F. PO-14
Pin, J.N. PO-59
Pircher, C. PO-49
Pittrow, D. OC-02
Plaisance, L. PO-41
Poenu, G. PO-41
Porcelli, M. PO-63
Porta, R. PO-54
Posch, F. PO-13
Preusser, M. PO-03
Pritchard, S.A. OC-09, PO-29
Provenzano, D. PO-49
Provenzano, L. PO-49
Prüller, F. PO-13
Psaroudakis, G. OC-16
Psyrris, A. PO-45
Ptohis, N. PO-39

Q

Quehenberger, P. PO-03
Quick, H. PO-31

R

Rabe, E. OC-02
Rabelo-Melo, F. OC-04
Rabensteiner, J. PO-13
Raggam, R.B. PO-13
Raimondo, M. PO-23
Rancoule, C. PO-22
Ranieri, G. PO-63
Reeves, B.N. PO-52
Ribera Fernández, P. PO-20
Rief, M. PO-13
Riley, P. PO-35
Rivera, M. OC-16
Robador, J.R. OC-03
Robertson, J. PO-29
Rocha Rondon, A.M. PO-30
Rogers, J. OC-15, PO-44
Rolling, C. PO-31
Rosell, A. PL-07, OC-04
Roy, P.G. OC-09
Rubino, M. PO-19
Ruiz, M. OC-01
Ruiz-Sada, P. PO-55
Rupérez, A. OC-01
Russo, L. OC-06, PO-04, PO-58

S

Sacco, C. PO-43
Saidak, Z. PO-50
Sala-Gonzalez, M.A. PO-14
Salas, E. OC-01
Salgado, M. OC-01, PO-20, PO-54
Samantas, E. PO-45
Samelis, G. PO-45
Sampietro, G. OC-06
Sánchez Cánovas, M. PO-20
Sanchez, A. PO-57
Sande-Sardina, L. PO-14
Sandset, P.M. OC-13
Sanfilippo, K.M. PL-04
Santiago-Gomez, A. PO-32
Santoro, A. PO-04
Sarropoulou, F. PO-15, PO-39, PO-40

AUTHOR INDEX

Sartori, S. PO-59
Sawant, S. PO-61
Sayar, Z. OC-11
Schaefer, B. OC-16
Schieppati, F. OC-06, PO-04, PO-08
Schimke, A. OC-02
Schirmer, A. PO-42
Schmidt, A. PO-42
Schneider, S.W. OC-03, OC-10
Schønfeldt Troelsen, F. PO-11
Schulenkorf, A. PO-31
Scott, H. OC-09
Sebelin, S. PO-59
Serrao, A. PO-58
Sevestre, M-A. PO-41, PO-50
Sharma, S. OC-15, PO-44
Shorova, M. PO-53
Silva-Cardenas, D.C. PO-14
Simioni, P. OC-07, PO-59
Sivera, P. PO-58
Skajaa, N. OC-12, PO-11, PO-18
Skjøth, F. OC-08
Skobridis, K. PO-34
Slavík, L. PO-48
Smith, I. PO-29
Soler, S. OC-14
Solomon, B. OC-15, PO-44
Sørensen, H.T. OC-12, PO-01, PO-12, PO-17, PO-18
Soria, J.M. OC-01
Soudet, S. PO-41, PO-50
Souto, J.C. PO-57
Spada, F. PO-19
Spiess, N. PO-33
Spinelli, D. OC-06, PO-04
Sposetti, C. PO-49
Squizzato, A. PO-43
Stadler, J. OC-03
Stambolieva, D. PO-53
Starostka, D. PO-48
Stephens, A. PO-37
Suchaud, J.P. PO-22
Svensson, A. OC-04

Sveshnikova, A.N. PO-27
Sveshnikova, E.A. PO-51
Svidelskaya, G.S. PO-51
Syrigos, N. PO-15, PO-39, PO-40
Szépligeti, S.K. PO-12
Szklańska, P.B. PO-08

T

Taylor, A. OC-11
Tardy, B. PO-05
Tardy-Poncet, B. PO-05
Tartari, C.J. OC-06, PO-04
Tekpli, X. OC-13
Temiño-Frances, M. PO-14
ten Cate, H. PL-21
ter Linden, E. PO-30
Tesakov, I.P. PO-27, PO-51
Thachill, J. OC-09
Thålin, C. OC-04
Thomas, M. OC-11
Thorlacius-Ussing, O. PO-02
Tiberio, G. OC-14
Ticozzi, C. OC-06, PO-04
Tie, J. OC-15, PO-44
Timotheadou, E. PO-45
Tinholt, M. OC-13
Tinquaut, F. PO-22
Toft Sørensen, H. PO-11
Torres, J. OC-15, PO-44
Tovey, H. PO-29
Troelsen, F.S. OC-12, PO-01, PO-12, PO-18
Trujillo-Santos, J. PO-55
Tselepis, A.D. PL-22, PO-34
Tsiakos, K. PO-15
Tsoukalas, N. PO-45
Tufano, A. PL-23
Turner, L. OC-09

U

Úlehlová, J. PO-48
Underhill, C. OC-15, PO-44
Ünlü, B. PO-26
Urbanic-Purkart, T. PO-13

V

Vágó, E.K. PO-01
van den Akker, R.F.P. PO-30
van Es, N. RT, OC-07, PO-01
van Vlijmen, B.J.M. PO-26
Vathiotis, I. PO-15
Velkova, E. PO-53
Veres, K. OC-12, PO-18
Versteeg, H.H. PO-26, PO-30
Verzeroli, C. OC-06, PO-04
Victor, C. PO-47
Vignoli, A. OC-06
Villa, B. PO-62
Villa, J.C. PO-54
Vinayagam, R. OC-09
Viñuela-Benítez, M.C. PO-57
Visonà, A. PO-55
Voigtlaender, M. PO-31
Volleamere, A. OC-09
von Campe, G. PO-13
Voulgari, P. PO-34

W

Wallén, H. OC-04
Wallenhorst, C. OC-16
Wang, T.F. PL-15
Wang, Y. OC-10
Ward, M.P. PO-06
Weiss, L. PO-08
Wilmlink, J.W. OC-07
Wilson, K.J. PO-52
Winkler, F. OC-03
Wolfe, R. OC-15, PO-44
Wong, H. OC-15, PO-44

Y

Yeini, E. PL-05
Yong, K. OC-11
Yuste, M. PO-62

Z

Zamora, C. PO-60
Zarrat, E. PO-41
Zumarraga-Cuesta, A. PO-14
Zwaan, S. PO-30
Zwicker, J.I. PL-26, PO-16

SATELLITE SYMPOSIA

(NOT CME ACCREDITED)



Bayer

May 28th, 2022

from 13:30 to 14:30

📍 Alabastro room - 2nd Floor

Holistic treatment of CAT: Peace of mind for concerned patients

Welcome to our patient's home:
laying the foundations
C. Ay

Building the walls of confidence:
preventing recurrence
A. Cohen

Roof of reassurance: tailoring protection
C. Becattini

Making it a home: patient's preference
M. Thomas

Panel and audience Q&A

Closing remarks
C. Ay



LEO Pharma

May 28th, 2022

from 13:30 to 14:30

📍 Oggioni room - Ground Floor

Managing Cancer Associated Thrombosis (CAT) - Is safety a concern?

Introduction & question and answer
S. Noble

Complexity of CAT & an update on
guidelines
A. Matzdorff

An update on the management of CAT
with LMWH
F. Langer

Managing patient adherence in CAT
L. Sardo

Q&A
facilitated by **S. Noble**

SATELLITE SYMPOSIA

(NOT CME ACCREDITED)

sanofi

Sanofi

May 28th, 2022

from 13:30 to 14:30

📍 Bianca room - 1st Floor

Cancer-associated thrombosis: where do we stand in 2022?

Welcome & introduction
A.J. Kakkar & A. Falanga

Understanding VTE risk in surgical and
medical cancer patients
G.T. Gerotziafas

Optimizing prevention of VTE in cancer
surgical patients
K. Syrigos

Individualizing treatment for cancer
associated VTE
A. Maraveyas

Panel discussion
A. Falanga & All

Conclusion and take-home messages
A. Falanga & A.J. Kakkar



GENERAL INFORMATION

Meeting venue

The Conference takes place in Bergamo at Centro Congressi Giovanni XXIII, placed in the city center, Viale Papa Giovanni XXIII, 106.

VIRTUAL PLATFORM

www.live.ichtic.com

After the registration deadline, registered participants receive an e-mail with a personal join code in order to enter the virtual platform of the event.

Organizing Secretariat

Servizi C.E.C. Srl

Via Daste e Spalenga 15 – 24125 Bergamo - Italy

e-mail: info@ichtic.com

Registration desk

The **registration desk** is located at the ground floor. It is staffed continuously every day of the conference. The staff is at your disposal for any information. Phone: +39 035 219927

On-site registration

Fees for on-site registration, VAT included are:

Delegate	€ 850,00
Student	€ 250,00
Accompanying person	€ 250,00

Message boards

Any late change in the program of the conference are notified by platform notifications.

Computing, printing and xeroxing

Available on request.

Continuing Medical Education (CME)

The 11th International Conference on Thrombosis and Hemostasis Issues in Cancer has been granted for CME accreditation by:



European Board for Accreditation in Hematology (EBAH)

The 11th International Conference on Thrombosis & Hemostasis Issues in Cancer (ICTHIC) ID 461735, has been reviewed and approved for CME-CPD accreditation by the European Board for Accreditation in Hematology (EBAH). The EBAH has ap-

proved this educational activity for a maximum number of **18.5 CME-CPD credits**. Each participant should only collect credits for time that she/he actually spent in the educational activity.



The European Accreditation Council for CME (EACCME) and Accreditation Council of Oncology in Europe (ACOE)

The 11th International Conference on Thrombosis and Hemostasis Issues in Cancer (ICTHIC), Bergamo, Italy, 27/05/2022-29/05/2022 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) for a maximum of **17 European CME credits** (ECMEC®s). Each medical specialist should claim only those credits that he/she actually spent in the educational activity.

Badges

All the in-person participants are kindly requested to wear the badge throughout the Conference. Only badge holders are admitted to the Scientific Sessions, Welcome Reception, Coffee Breaks and Lunches. For the Social Events please bring with you the ticket(s) delivered at registration.

Certificates of Attendance

In person participants: participants will be able to pick up the certificate of participation at the self-registration totems on Sunday May 29th, starting from 13.00.

Virtual participants: virtual participants will be able to download the certificate directly from the platform on Sunday May 29th starting from 13.00.

GENERAL INFORMATION

Oral Communications

Presentation & Discussion

Time at disposal for each Oral Communication is 15 minutes (10 minutes for presentation + 5 minutes for questions/discussion at the end of each speech).

At the end of the presentation, the chairs of the session handle the Q&A /discussion:

- in the plenary room for in person participants
- using the chat /questions box of the virtual platform for virtual participants.

Posters

Viewing Time

Posters pdf and videos of the pre-recorded poster presentations can be viewed in the Poster Area of the virtual platform.

Mandatory attendance

Poster authors are requested to be present at the start and during the entire Poster discussion Session.

Discussion

There are 8 Poster Discussion Sessions (duration: 1 hour), each guided by a chair and all held on Saturday, May 28th:

Poster Session 1:

Biomarkers/Hypercoagulability II
Bianca Room - 1st floor

Poster Session 2:

Bleeding complications
Oggioni Room - Ground Floor

Poster Session 3:

Epidemiology
Alabastro Room - 2nd floor

Poster Session 4:

Hemostatic proteins and cancer biology
Novelli Room - 2nd floor

Poster Session 5:

Therapeutic challenges
Oggioni Room - Ground Floor

Poster Session 6:

Thromboprophylaxis and thrombotic risk assessment
Novelli Room - 2nd floor

Poster Session 7:

Biomarkers/Hypercoagulability II
Bianca Room - 1st floor

Poster Session 8:

Treatment of thrombosis in cancer
Alabastro Room - 2nd floor

Each presenter has 3 minutes to sum up his/her poster and 2 minutes for the Q&A/discussion with the chair and participants.

The chair of each session handles the questions:

- in each poster session room for in person participants
- using the chat /questions box of the virtual platform for virtual participants

Slide Center

Slide center is located at **ground floor**. All presenters should check in their slides, pen-drive containing a PowerPoint presentation in 16:9, no later than 2 hours prior to the start of their session. Presentation must be Microsoft Power Point/Keynote file and PC/MAC compatible.

Virtual presenters are requested to send their presentation in PowerPoint/Keynote in 16:9 (please specify if containing video/audio) to the Organizing Secretariat (info@icthic.com) at least within the day before of the respective session. Presenters are requested to present the slides with share screen function, please avoid too much heavy presentations and are also requested to be present at the start and during the entire session.

Language

The official language of the Conference is English. Translations are not provided.

Meals

Coffee/tea breaks and lunches are included in the Conference fee and are served in the Catering Areas.



SOCIAL PROGRAM

Friday May 27th, 2022

Tuk tuk tour: Art, Nature and Landscapes

14.15 Meeting point with the guide at the congress venue, Centro Congressi Giovanni XXIII (Viale Papa Giovanni XXIII 106, Bergamo)

14.30 Tuk tuk tour

The tour, before reaching the monumental center of **Piazza Duomo** in the **Upper Town**, allows you to discover how many green areas, gardens, parks and vegetable gardens Bergamo offers.

The itinerary includes a visit to **Palazzo Moroni** with its gardens and the **Monastery of Astino**. An unusual itinerary full of meadows, vineyards, flowered balconies and priceless views.

17.30 Return to the congress venue

Saturday May 28th, 2022

8.00 - 16.30 Visit of Parma

Morning:

07.45 Meeting point at the congress venue, Centro Congressi Giovanni XXIII (Viale Papa Giovanni XXIII 106, Bergamo)

08.00 Departure by bus to Sant'Agata di Villanova sull'Arda (PC)

Visit to **Villa Verdi**, the country estate that Verdi chose as his residence during the years of maturity and success.

Transfer by bus to Roncole Verdi (PR)

Visit of the outside of **Verdi's birthplace** and the church of S. Michele Arcangelo.

Visit to the aging cellars of **Culatello di Zibello**.

Lunch

Afternoon:

Transfer by bus to Parma

Guided tour of **Parma city center** on foot, to discover the main monuments of the historic center:

Piazzale della Pace with the outside of Monumental Complex of the Pilotta and Teatro Farnese, a sumptuous seventeenth-century structure completely built in wood; Teatro Regio and the outside of Basilica della Steccata (containing the latest masterpiece of Parmigianino), Piazza Garibaldi; in Piazza Duomo visit of the Cathedral (Deposition of the sculptor-architect Benedetto Antelami, masterpiece of Correggio), and the exterior of the Baptistery, a shining example of fusion between painting, sculpture and architecture of the Romanesque-Gothic period.

16.30 Return to Bergamo by bus



SPONSOR

Platinum



Gold



Daiichi-Sankyo

Silver



Bronze





icthic.com